

**EDITORIAL CONTACTS:**

Sarina Chohan
(916) 371-7974
schohan@lipomics.com

Agency Contact
Doug Forsyth, Alchymia Communications
(541) 482-8744
df@alchymiacomm.com

Lipomics Technologies Sign Research Collaboration Agreement for Pharmacometabolic Markers

WEST SACRAMENTO, Calif., May 21, 2007 - Lipomics Technologies, Inc., a privately held company that specializes in the analysis of lipid metabolites, announced today that they have entered into a two year collaborative research agreement with Duke University in several key clinical areas to identify pharmacometabolomic markers. Lipomics will provide Duke analytical services for biomarker discovery and validation (using its proprietary platform and technologies relating to lipid profiles) as well as provide data transfer and interpretation services that will streamline the process of biomarker development allowing researchers at Duke easy access to analysis and data. In return, Lipomics will receive an option to license diagnostic rights on all such markers developed under this agreement through use of Lipomics proprietary technologies. Initial clinical areas are CNS (schizophrenia and depression) and Cardiovascular (response to statins) disorders.

Results from the first project of the collaboration were presented at the Society of Biological Psychiatry meeting in San Diego on May 18th, 2007. The study aimed to define metabolic signatures for patients treated with anti-psychotic drugs.

“We are very excited about this partnership. It is a great honor to work with Duke University, one of the leading academic institutions in the country, to advance our clinical diagnostic program” said Dr. Meeta Patnaik, chief medical officer, Lipomics.

Financial terms of the collaboration were not disclosed.

About Lipomics

Lipomics develops tools for drug discovery and personalized medicine using proprietary technologies for lipid metabolism analysis and data interpretation. We generate a comprehensive understanding of lipid metabolism from plasma, serum or tissue samples by combining quantitative measurements of lipid metabolites with proprietary algorithms for mapping the



lipomic profiles to biochemical pathways. In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technology to speed drug discovery processes, improve clinical trial stratification, reduce late-stage drug attrition, discover new biomarkers and develop early tests for monitoring drug response. More information about Lipomics can be found at www.lipomics.com

#